or Try an Advanced Search...

    Technical Analysis for GANX - Gain Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 1.66 -3.49% -0.06
    GANX closed down 3.49 percent on Wednesday, November 20, 2024, on 42 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical GANX trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction -3.49%
    Lower Bollinger Band Walk Weakness -3.49%
    Inside Day Range Contraction -3.49%
    Wide Bands Range Expansion -3.49%
    Oversold Stochastic Weakness -3.49%
    180 Bearish Setup Bearish Swing Setup -1.78%
    Lower Bollinger Band Walk Weakness -1.78%
    Outside Day Range Expansion -1.78%
    Older End-of-Day Signals for GANX ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 17 hours ago
    Fell Below Previous Day's Low about 17 hours ago
    Possible NR7 about 19 hours ago
    Possible Inside Day about 19 hours ago
    Down 3% about 19 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    GANX Chart by TradingView
    Basic chart:

    Profile

    Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Allosteric Regulation Sumitomo Group

    Is GANX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 Gain Therapeutics GAAP EPS of -$0.17
    Nov 14 Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
    Oct 23 Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2
    Oct 15 Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
    Oct 9 Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference
    Oct 7 Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
    Oct 3 Gain Therapeutics to Participate at Upcoming Investor Conferences
    Sep 30 Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
    Sep 26 Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
    Sep 19 Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
    See more GANX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.33
    52 Week Low 0.89
    Average Volume 337,505
    200-Day Moving Average 2.43
    50-Day Moving Average 2.05
    20-Day Moving Average 2.17
    10-Day Moving Average 1.94
    Average True Range 0.25
    RSI (14) 35.90
    ADX 31.02
    +DI 10.87
    -DI 22.35
    Chandelier Exit (Long, 3 ATRs) 2.07
    Chandelier Exit (Short, 3 ATRs) 2.35
    Upper Bollinger Bands 2.81
    Lower Bollinger Band 1.54
    Percent B (%b) 0.1
    BandWidth 58.84
    MACD Line -0.13
    MACD Signal Line -0.04
    MACD Histogram -0.0892
    Fundamentals Value
    Market Cap 26.89 Million
    Num Shares 16.2 Million
    EPS -1.81
    Price-to-Earnings (P/E) Ratio -0.92
    Price-to-Sales 1400.35
    Price-to-Book 10.70
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.87
    Resistance 3 (R3) 1.88 1.81 1.84
    Resistance 2 (R2) 1.81 1.76 1.81 1.82
    Resistance 1 (R1) 1.74 1.73 1.71 1.73 1.81
    Pivot Point 1.67 1.67 1.66 1.67 1.67
    Support 1 (S1) 1.60 1.62 1.57 1.59 1.51
    Support 2 (S2) 1.53 1.59 1.53 1.50
    Support 3 (S3) 1.46 1.53 1.49
    Support 4 (S4) 1.45